临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 139264-17-8

Zolmitriptan

中文名称:佐米曲普坦
CAS号:139264-17-8
分子式: C16H21N3O2 分子量: 287.36
产品形式: free base
研发状态: Completed
研发用途: Healthy
研究机构: Parc de Salut Mar; Food and Drug Administration (FDA)
研发日期: July 12 2023
研发阶段: Phase 1
Zolmitriptan(BW-311C90) is a novel and highly selective 5-HT(1B/1D) receptor agonist, used in the treatment of acute migraines.

CAS: 1392275-56-7

Tenofovir alafenamide hemifumarate

中文名称:替诺福韦艾拉酚胺富马酸盐
CAS号:1392275-56-7
分子式: C46H62N12O14P2 分子量: 1069.00
产品形式: Hemifumarate
研发状态: Not yet recruiting
研发用途: Healthy Volunteer; Weight Gain; Metabolic Effects; Integrase Strand Transfer Inhibitors
研究机构: National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health Clinical Center (CC)
研发日期: May 15 2024
研发阶段: Phase 2
Tenofovir alafenamide (TAF, GS-7340) hemifumarate is a prodrug of tenofovir but results in significantly higher intracellular tenofovir concentrations and lower serum levels. Tenofovir alafenamide is a novel nucleotide reverse transcriptase inhibitor for the treatment of HIV-1 infection.

CAS: 1392136-43-4

Verdinexor (KPT-335)

中文名称:Verdinexor(KPT-335)抑制剂
CAS号:1392136-43-4
分子式: C18H12F6N6O 分子量: 442.32
产品形式: free base
研发状态: Terminated
研发用途: Healthy
研究机构: Karyopharm Therapeutics Inc
研发日期: May 26 2015
研发阶段: Phase 1
Verdinexor (KPT-335, ATG-527) is an orally bioavailable, selective XPO1/CRM1 inhibitor.

CAS: 139110-80-8

Zanamivir

中文名称:扎那米韦
CAS号:139110-80-8
分子式: C12H20N4O7 分子量: 332.31
产品形式: free base
研发状态: Recruiting
研发用途: Dengue Fever
研究机构: George Washington University; Naval Medical Research Center; Clinica de la Costa; Global Disease Research
研发日期: March 15 2024
研发阶段: Early Phase 1
Zanamivir (GG167,GR 121167X) is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A virus and influenza B virus.

CAS: 1388803-90-4

Vodobatinib (K0706)

CAS号:1388803-90-4
分子式: C27H20ClN3O2 分子量: 453.92
产品形式: Free Base
研发状态: Active not recruiting
研发用途: Early Parkinson Disease
研究机构: Sun Pharma Advanced Research Company Limited
研发日期: February 18 2019
研发阶段: Phase 2
Vodobatinib (K0706, SCO-088, SUN K706, SUN-K0706) is a novel BCR-ABL1 tyrosine kinase inhibitor with an IC50 of 7 nM. Vodobatinib exhibits activity against most BCR-ABL1 point mutants with IC50s of 167 nM, 154 nM,165 nM and 1967 nM for BCR-ABL1L248R, BCR-ABL1Y253H , BCR-ABL1E255V and BCR-ABL1T315I, respectively.

CAS: 1388651-30-6

Elenbecestat

CAS号:1388651-30-6
分子式: C19H18F3N5O2S 分子量: 437.44
产品形式: Free base
研发状态: Completed
研发用途: Healthy Participants
研究机构: Eisai Co. Ltd.; Eisai Inc.
研发日期: February 14 2017
研发阶段: Phase 1
Elenbecestat (E2609) is a novel BACE1 inhibitor, demonstrating prolonged reductions in plasma beta-amyloid levels after single dosing.